Infusion of Megakaryocytic Progenitor Products Generated from Cord Blood Hematopoietic Stem/Progenitor Cells: Results of the Phase 1 Study

Xi, Jiafei; Zhu, Honghu; Liu, Daqing; Nan, Xue; Zheng, Wen; Liu, Kaiyan; Shi, Wei; Chen, Lin; Lv, Yang; Yan, Fang; Li, Yanhua; Xie, Xiaoyan; Wang, Yunfang; Yue, Wen; Xu, Xin; Wei, Xiaofei; Zhu, Jun; Huang, Xiaojun; Pei, Xuetao
February 2013
PLoS ONE;Feb2013, Vol. 8 Issue 2, p1
Academic Journal
Background: Currently, a constant shortage in the supply of platelets has become an important medical and society challenge, especially in developing country, and the in vitro production of megakaryocytic progenitor cells (MPs) from cord blood could represent an effective platelet substitute. In the present study, our objective was to determine the safety and feasibility of ex vivo generated MPs in patients. Methods and Findings: MPs were produced and characterized from cord blood mononuclear cells under a serum free medium with cytokines. We investigated the feasibility of expansion and infusion of cord blood-derived MPs in 24 patients with advanced hematological malignancyes. The primary end point was the safety and tolerability of the infusion of cord blood-derived MPs. No adverse effects were observed in patients who received ex vivo-generated cells at concentrations of up to a median value of 5.45×106cells/kg of body weight. With one year follow-up, acute and chronic GVHD had not been observed among patients who received MPs infusion, even without ABO blood group and HLA typing matching. Conclusions: These initial results in patients are very encouraging. They suggest that infusion of cord blood-derived MPs appears safe and feasible for treatment of thrombocytopenia. Trial Registration: www.chictr.org ChiCTR-TCH-09000333.


Related Articles

  • Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy. Sanjuan-Pla, Alejandra; Macaulay, Iain C.; Jensen, Christina T.; Woll, Petter S.; Luis, Tiago C.; Mead, Adam; Moore, Susan; Carella, Cintia; Matsuoka, Sahoko; Jones, Tiphaine Bouriez; Chowdhury, Onima; Stenson, Laura; Lutteropp, Michael; Green, Joanna C. A.; Facchini, Raffaella; Boukarabila, Hanane; Grover, Amit; Gambardella, Adriana; Thongjuea, Supat; Carrelha, Joana // Nature;10/10/2013, Vol. 502 Issue 7470, p232 

    The blood system is maintained by a small pool of haematopoietic stem cells (HSCs), which are required and sufficient for replenishing all human blood cell lineages at millions of cells per second throughout life. Megakaryocytes in the bone marrow are responsible for the continuous production of...

  • Blood Cancer Update.  // PharmaWatch: Cancer;Sep2005, Vol. 4 Issue 9, p16 

    The article presents news briefs related to developments in the field of blood cancer treatment. Investigators from the University's School of Medicine have found that a protein called NF-Ya activates several genes known to regulate the development of hematopoietic stem cells or blood-producing...

  • Synergistic effects of pegylated recombinant human megakaryocyte growth and development factor and granulocyte colony-stimulating factor on mobilization of hematopoietic progenitor and stem cells with long-term repopulating ability into peripheral... Honda, K; Takenaka, K; Shinagawa, K; Ishimaru, F; Ikeda, K; Niiya, K; Harada, M // Bone Marrow Transplantation;8/15/2001, Vol. 28 Issue 4, p329 

    We investigated the effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on peripheral blood progenitor cell (PBPC) mobilization and the combined effect of PEG-rHuMGDF plus recombinant human granulocyte colony-stimulating factor (rhG-CSF) in C57BL/6...

  • The Use of Adenoviral Vectors for Genetic Manipulation and Analysis of Primitive Hematopoietic Cells. Jordan, Craig T.; Vanin, Elio F.; Marini, Frank C. // Current Gene Therapy;Sep2001, Vol. 1 Issue 3, p257 

    Gene transfer into stem cells has long been studied as a means by which primitive hematopoietic cells could be characterized and manipulated. While a variety of strategies have been attempted, it still remains relatively difficult to perform direct stem cell analysis. In this review, we examine...

  • Prolonged isolated thrombocytopenia after hematopoietic stem cell transplantation: morphologic correlation. Bielski, M; Yomtovian, R; Lazarus, H M; Rosenthal, N // Bone Marrow Transplantation;12/1/98, Vol. 22 Issue 11, p1071 

    Prolonged isolated thrombocytopenia, defined as recovery of other cell counts with continuous dependence on platelet transfusions for greater than 90 days after hematopoietic stem cell transplantation (HSCT), develops in approximately 5% of patients who undergo HSCT. Although the clinical...

  • Targeting exogenous genes to tumor angiogenesis by transplantation of genetically modified hematopoietic stem cells. De Palma, Michele; Venneri, Mary Anna; Roca, Cristina; Naldini, Luigi // Nature Medicine;Jun2003, Vol. 9 Issue 6, p789 

    Angiogenic tumor vessels are promising targets for the activity and the selective delivery of cancer therapeutics[SUP1,2]. The bone marrow contributes different cell types to the tumor stroma, including hematopoietic cells[SUP3,4] and, as recently suggested, vascular endothelial cells...

  • Companies use many methods to select elusive stem cells. McIntosh, Hugh // JNCI: Journal of the National Cancer Institute;05/01/96, Vol. 88 Issue 9, p573 

    Examines technologies used in the generation of hematopoietic stem cell selectors. Ceprate SC System; RPR Gencell; Baxter Health Care's Isolex 300; Systemix.

  • 708. Combination of Allogeneic Hematopoietic Stem Cell Transplantation and Allogeneic MHC Gene Transfer Against Solid Cancers Aoki, Kazunori; Ohashi, Masaki; Kushida, Miwa; Yoshida, Kimiko; Mandai, Masaki; Nabel, Gary J.; Yoshida, Teruhiko // Molecular Therapy;Jun2005, Vol. 11, p274 

    An abstract of the article "Combination of Allogeneic Hematopoietic Stem Cell Transplantation and Allogeneic MHC Gene Transfer Against Solid Cancers," by Kazunori Aoki, Masaki Ohashi, Miwa Kushida, Kimiko Yoshida, Masaki Mandai, Gary J. Nabel and Teruhiko Yoshida is presented.

  • Differential Expression of Novel Potential Regulators in Hematopoietic Stem Cells. Forsberg, E. Camilla; Prohaska, Susan S.; Katzman, Sol; Heffner, Garrett C.; Stuart, Josh M.; Weissman, Irving L.; Roopenian, Derry // PLoS Genetics;Sep2005, Vol. 1 Issue 3, p281 

    The hematopoietic system is an invaluable model both for understanding basic developmental biology and for developing clinically relevant cell therapies. Using highly purified cells and rigorous microarray analysis we have compared the expression pattern of three of the most primitive...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics